LATEST NEWS

News Releases
news icon
29 July 2025
NanoCell Announces Publication of Research Data in Journal for ImmunoTherapy of Cancer Demonstrating First-in-Class Non-Viral DNA-Based In Vivo CAR-T Generation
news icon
16 June 2025
NanoCell Secures Seed-Extension Financing from The Institute for Follicular Lymphoma Innovation to Advance Lead Clinical Candidate for B Cell Malignancies
news icon
4 February 2025
NanoCell Therapeutics Announces Upcoming Participation in Investor Conferences
news icon
8 November 2024
NanoCell Therapeutics Announces Animal Proof of Concept Data Demonstrating Non-viral DNA Delivery for In Vivo CAR-T Cell Generation
news icon
22 October 2024
NanoCell Therapeutics Announces Upcoming Participation in Investor and Scientific Conferences
news icon
16 May 2024
NanoCell Therapeutics Inc. and OneChain Immunotherapeutics S.L Announce Collaboration on In Vivo CAR-T Therapy for B-cell Lymphoma
news icon
19 March 2024
NanoCell Therapeutics Inc. Appoints Charles F. Albright, PhD, to its Scientific Advisory Board
news icon
26 September 2023
NanoCell Therapeutics Inc. Appoints Dr. Jacek Lubelski, PhD as Chief Technology Officer
news icon
3 August 2023
NanoCell Therapeutics Inc. Appoints Florence Salmon, PhD to its Scientific Advisory Board
news icon
4 January 2023
NanoCell Theapeutics Inc, in Consortium with Leading Research Organizations, Secures Multimillion Euro HORIZON-EIC Pathfinder Challenges Grant for Pioneering Gene Therapy Platform
Contact Details

Head Office:

NanoCell Therapeutics Inc.
1055 Westlakes Dr
STE 300
Berwyn, PA 19312-2410
United States

Follow Us